SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Arvinas to Present Preliminary ARV-393 Phase 1 Data at ASH

Arvinas plans to present preliminary clinical data from early monotherapy dose-escalation cohorts in the ARV-393 Phase 1 trial at the 2026 American Society of Hematology Annual Meeting. The presentation will include safety, pharmacokinetics and pharmacodynamics data from all patients.

ARVN

Related stories